Physicians' Academy for Cardiovascular Education
Lessons from landmark trials with PCSK9i: Why, who and how to manage patients at increased CV risk?

Lessons from landmark trials with PCSK9i: Why, who and how to manage patients at increased CV risk?

CME accredited E-Learning

Online-CME - This course consists of 4 separate lectures

This CME accredited course consists of 4 separate short (12 - 15 minute) lectures. View and complete all 4 items separately and earn 1 CME credit

In this educational programme the role of PCSK9 inhibitors in the management of patients at increased CV risk will be discussed, based on new data from recent landmark outcome trials.

This course consists of the following 4 lectures

Educational objectives of this course are to:

Expert faculty

Target audience

This educational activity is designed for cardiologists and other healthcare professionals with an interest in treating patients with increased CV risk, ACS and lipid disorderes

CME accreditation

This online course is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).

Funding

Supported by an unrestricted educational grant received from Sanofi-Regeneron

Online-CME

This is available as accredited online CME for members. Click the button below to enroll:

Enroll

Share this page with your colleagues and friends: